by Maria Zannes | Sep 14, 2021 | Press Releases
CyPath® Lung, an Innovative Lung Cancer Diagnostic, Fully Validated as a Laboratory Developed Test (LDT) by CAP/CLIA-Certified Laboratory SEPTEMBER 9, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held biotech company advancing innovative cancer...
by Maria Zannes | Sep 10, 2021 | Events
bioAffinity Technologies President and CEO Maria Zannes will present the Company’s recent advancements in commercializing CyPath® Lung, a noninvasive test to diagnose early stage lung cancer and meet with investors at H.C. Wainwright & Company’s 23rd Annual Global...
by Maria Zannes | Aug 12, 2021 | Press Releases
AUGUST 12, 2021 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced publication in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper, entitled Quality-Controlled...
by Dale Harrison | Aug 9, 2021 | Publications
Journal of Visualized Experiments (JoVE) – August 9, 2021 AuthorsMarcia Grayson, Shao-Chiang Lai, Lydia H. Bederka, Patricia Araujo, Jamila Sanchez, Xavier T. Reveles, Vivienne I. Rebel, Jennifer Rebeles AbstractSputum, widely used to study the cellular content and...
by Dale Harrison | Jul 2, 2021 | Publications
“Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11, June 26 through July 2, 2021 Authors David J. Elzi, William E. Bauta,...
